DE69634414D1 - Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie - Google Patents

Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie

Info

Publication number
DE69634414D1
DE69634414D1 DE69634414T DE69634414T DE69634414D1 DE 69634414 D1 DE69634414 D1 DE 69634414D1 DE 69634414 T DE69634414 T DE 69634414T DE 69634414 T DE69634414 T DE 69634414T DE 69634414 D1 DE69634414 D1 DE 69634414D1
Authority
DE
Germany
Prior art keywords
isochinolinsulfonyl
gluckom
okular
ischemia
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634414T
Other languages
English (en)
Other versions
DE69634414T2 (de
Inventor
A Kapin
M Desantis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of DE69634414D1 publication Critical patent/DE69634414D1/de
Application granted granted Critical
Publication of DE69634414T2 publication Critical patent/DE69634414T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69634414T 1995-12-21 1996-12-20 Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie Expired - Fee Related DE69634414T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US935195P 1995-12-21 1995-12-21
US9351P 1995-12-21
PCT/US1996/020197 WO1997023222A1 (en) 1995-12-21 1996-12-20 Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia

Publications (2)

Publication Number Publication Date
DE69634414D1 true DE69634414D1 (de) 2005-04-07
DE69634414T2 DE69634414T2 (de) 2005-11-17

Family

ID=21737108

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634414T Expired - Fee Related DE69634414T2 (de) 1995-12-21 1996-12-20 Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie

Country Status (14)

Country Link
US (2) US6271224B1 (de)
EP (1) EP0868186B1 (de)
JP (1) JP3719609B2 (de)
KR (1) KR100452715B1 (de)
CN (1) CN1155383C (de)
AT (1) ATE289815T1 (de)
AU (1) AU720326B2 (de)
DE (1) DE69634414T2 (de)
ES (1) ES2238702T3 (de)
HK (1) HK1015691A1 (de)
MX (1) MX9805033A (de)
PT (1) PT868186E (de)
TW (1) TW534814B (de)
WO (1) WO1997023222A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
EP1459743B9 (de) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Verbindung zur Vorbeugung und Behandlung von Glaukoma
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
AU4144400A (en) 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
EP1064944A1 (de) * 1999-06-25 2001-01-03 Schering Aktiengesellschaft Protein-Kinase N Hemmer enthaltend Fasudil
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
PL211494B1 (pl) * 2001-12-21 2012-05-31 Alcon Zastosowanie syntetycznych, nieorganicznych nanocząstek jako nośników dla leków i kompozycja farmaceutyczna do oczu lub uszu
WO2003059263A2 (en) * 2001-12-21 2003-07-24 Alcon, Inc. Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions.
US20050245509A1 (en) * 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
CA2506464C (en) 2002-11-18 2012-07-31 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
EP1550446A1 (de) * 2003-11-14 2005-07-06 Switch Biotech Aktiengesellschaft Verwendung von 1-(5-Isochinolinsulfonyl)homopiperazin zur Behandlung und Vorbeugung von Hypopigmentstörungen
ES2426288T3 (es) 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
MXPA06006862A (es) * 2003-12-22 2007-01-26 Alcon Inc Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular.
CN1897972A (zh) * 2003-12-22 2007-01-17 爱尔康公司 用于治疗青光眼性视网膜病和视神经病的活性剂
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
CA2559630C (en) 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
AU2005322338B2 (en) * 2004-12-27 2011-06-09 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
KR101333970B1 (ko) 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
JP5220414B2 (ja) * 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
CN100367967C (zh) * 2005-12-12 2008-02-13 天津红日药业股份有限公司 一种盐酸法舒地尔口服制剂
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
JP2009521494A (ja) * 2005-12-22 2009-06-04 アルコン リサーチ， リミテッド ｒｈｏキナーゼ媒介性疾患および状態を治療するための（インダゾール−５−イル）−ピラジンおよび（１，３−ジヒドロインドール−２−オン）−ピラジン
CA2653424A1 (en) 2006-06-08 2007-12-13 Ube Industries, Ltd. Novel indazole derivative having spiro ring structure in side chain
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
WO2008105058A1 (ja) * 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
JP5234825B2 (ja) 2007-07-02 2013-07-10 旭化成ファーマ株式会社 スルホンアミド化合物及びその結晶
US20120101167A1 (en) * 2010-10-25 2012-04-26 Langham Maurice E Treatment of ocular and cerebral ischemia
CN102028694B (zh) * 2010-11-12 2012-03-14 天津红日药业股份有限公司 法舒地尔经眼部给药用于制备治疗青光眼药物中的应用
AU2011345969B2 (en) * 2010-12-22 2016-04-21 D. Western Therapeutics Institute, Inc. Novel substituted isoquinoline derivative
TW202239413A (zh) 2011-02-04 2022-10-16 日商興和股份有限公司 眼科用製劑
CN102138895B (zh) * 2011-03-30 2013-01-23 天津红日药业股份有限公司 一种含盐酸法舒地尔的滴眼剂及其制备
US8980910B2 (en) * 2011-04-01 2015-03-17 Indiana University Research And Technology Corporation Treatment of glaucoma
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
JP2013129604A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する徐放性フィルム製剤
JP2013129605A (ja) * 2011-12-20 2013-07-04 Kowa Co 緑内障治療薬を含有する安定なフィルム製剤
EP2628482A1 (de) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
CN105050600B (zh) 2013-04-24 2018-09-28 国立大学法人九州大学 眼底疾病治疗剂
US9682130B2 (en) * 2015-09-25 2017-06-20 Okogen, Llc Viral conjunctivitis treatment using Ranpirnase and/or Amphinase
EP4088719A1 (de) * 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
WO2017064119A1 (en) * 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
TWI788484B (zh) 2017-12-21 2023-01-01 日商參天製藥股份有限公司 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
WO2022047315A1 (en) * 2020-08-31 2022-03-03 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
NZ200429A (en) 1981-04-30 1984-10-19 Smith & Nephew Ass Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye
US4730013A (en) 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CA2131101A1 (en) * 1992-05-13 1993-11-25 Louis Desantis Jr. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
EP1285657A3 (de) 1993-10-13 2003-08-20 Allergan, Inc. Verfahren zur Verwendung von (2-imidazolin-2-yl-amino) Quinoxalinderivaten
CA2153979C (en) * 1993-12-08 2003-10-21 Mark Hellberg Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
ES2160700T3 (es) 1994-01-24 2001-11-16 Allergan Sales Inc Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a.
JPH07277979A (ja) 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy

Also Published As

Publication number Publication date
HK1015691A1 (en) 1999-10-22
US6403590B1 (en) 2002-06-11
KR100452715B1 (ko) 2004-12-17
WO1997023222A1 (en) 1997-07-03
CN1155383C (zh) 2004-06-30
AU720326B2 (en) 2000-05-25
PT868186E (pt) 2005-05-31
JP2001509780A (ja) 2001-07-24
US6271224B1 (en) 2001-08-07
KR19990076580A (ko) 1999-10-15
CN1207680A (zh) 1999-02-10
EP0868186B1 (de) 2005-03-02
MX9805033A (es) 1998-09-30
EP0868186A1 (de) 1998-10-07
JP3719609B2 (ja) 2005-11-24
DE69634414T2 (de) 2005-11-17
TW534814B (en) 2003-06-01
ES2238702T3 (es) 2005-09-01
AU1464497A (en) 1997-07-17
ATE289815T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DK112190A (da) Prostaglandinderivater til behandling af glaukom eller foroeget okulaert tryk
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
ATE418989T1 (de) Verwendung von sub-antimikrobiellen tetracyclinen zur behandlung von okularer rosacea
DE3872701T2 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
EA200300560A1 (ru) Улучшенный способ лечения
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
HK1045645A1 (zh) 消除角膜瘢痕、渾濁化和混濁的生化方法
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
DE69420832T2 (de) Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
ATE23112T1 (de) Verwendung von 1-(p-isopropoxyethoxymethylphenoxy)-3-isopropylamino-propan-2-ol zur herstellung eines arzneimittels zur senkung des augeninnendrucks.
DE69905489T2 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
CA2240271A1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
RU93025693A (ru) Способ хирургического лечения близорукости
BROWN DR. WM. L. NOBI, E, President.
RU95107756A (ru) Способ лечения прогрессирующей миопии
UA30491A (uk) Броберон- блокатор адренергічних нейронів нового покоління
JO1317B1 (en) Eye treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee